Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

  • beavertail_splash beavertail_splash Mar 25, 2013 8:46 AM Flag

    Ted is proved better than LIN on tolerance

    "As in the ESTABLISH 1 study, both tedizolid and linezolid were generally well tolerated in ESTABLISH 2 with drug-related treatment emergent adverse events (TEAE) reported in 20.5% of tedizolid patients versus 24.8% of linezolid treated patients. Gastrointestinal adverse events were the most commonly reported of all TEAEs (16.0% in tedizolid vs. 20.5% in linezolid).

 
TSRX
13.630.0000(0.00%)Sep 11 4:00 PMEDT